No, a Single Dose of Fosfomycin is Insufficient to Complete a 5-Day Course for ESBL UTI
After 5 days of IV ceftazidime/avibactam for an ESBL urinary infection, you should NOT use a single 3-gram dose of fosfomycin to complete therapy. Instead, continue oral fosfomycin at 3 grams once daily for the remaining duration to complete a total 7-day treatment course.
Why Single-Dose Fosfomycin is Inappropriate Here
The FDA-approved indication for single-dose fosfomycin (3 grams once) is exclusively for uncomplicated cystitis in women 1. Your patient has a complicated UTI requiring IV therapy, which fundamentally changes the treatment paradigm.
Current guidelines explicitly state that for adult cystitis, fosfomycin is given as a single dose 2, 3. However, these same guidelines note there is insufficient evidence to recommend fosfomycin for pyelonephritis or complicated UTI 2. The guideline table specifically lists "Clinical review, not enough evidence to provide a clear recommendation for duration of treatment" for fosfomycin in adult pyelonephritis 2.
The Correct Approach: Daily Fosfomycin for Step-Down Therapy
The most recent high-quality evidence demonstrates that oral fosfomycin 3 grams ONCE DAILY (not single-dose) is effective as step-down therapy for complicated ESBL UTIs 4. This 2026 multicenter randomized controlled trial showed:
- Patients who improved after 3-7 days of IV antibiotics for ESBL UTI were randomized to either continue IV therapy OR switch to oral fosfomycin 3 grams once daily
- Clinical cure rates were comparable: 92.8% (fosfomycin) vs 95.2% (IV therapy)
- This was noninferior and represents a carbapenem-sparing strategy
Practical Treatment Algorithm
For your patient who has received 5 days of IV ceftazidime/avibactam:
- Confirm clinical improvement (resolution of fever, flank pain, systemic symptoms)
- Switch to oral fosfomycin 3 grams once daily (not single-dose)
- Complete a total 7-day course (so 2 more days of daily fosfomycin) 5
The FDA label for Zerbaxa specifies 7 days total duration for complicated UTI including pyelonephritis 5.
Supporting Evidence for Multi-Dose Fosfomycin
A 2016 retrospective study showed that fosfomycin dosed every 48-72 hours (not single-dose) was non-inferior to ertapenem for outpatient ESBL UTI treatment 6. Common regimens were:
- 3 grams every 72 hours (62% of patients)
- 3 grams every 48 hours (23% of patients)
This reinforces that repeated dosing is necessary for complicated infections, not the single-dose regimen approved only for uncomplicated cystitis.
Critical Pitfalls to Avoid
- Do not confuse uncomplicated cystitis dosing with complicated UTI dosing: Single-dose is only for simple bladder infections in otherwise healthy women
- Do not underdose: Your patient needs daily fosfomycin, not a one-time dose
- Do not extend beyond 7 days total: The evidence supports 7 days total duration for complicated UTI 5
Why This Matters for Outcomes
Using inadequate antibiotic duration or dosing increases risk of:
- Treatment failure and symptom recurrence
- Development of resistance
- Need for hospital readmission
- Potential progression to urosepsis
The 2026 RCT specifically demonstrated that proper daily fosfomycin dosing achieved 98% microbiological cure rates in ESBL UTIs 4, but this requires appropriate dosing frequency and duration.